Anavex Life Sciences Corp (AVXL)

[12x]

This Misling interview on biospace only talks about the AUC (so anchoring was considered part of it?). Doc explained the co-primary preclude anchoring and Misling confirmed “No AUC” in 2022 Q3 CC. However, according to the interview, the Dec 2021 endpoint change was 3 months after trial had ended and clinical trials.gov updated endpoints in January. So there is still a chance Anavex will update the endpoint in September/October. If either AUC or anchoring are back in the .gov, I am out.

Thanks to George’s old post, here is Avartar presentation and avatar CC